| SC 13G | 2020-02-07 | BlackRock Inc. | Axsome Therapeutics, Inc. | 2,160,246 | 5.9% | EDGAR |
| SC 13G | 2019-01-28 | Venrock Healthcare Capital Partners II, L.P. | Axsome Therapeutics, Inc. | 1,640,000 | 5.0% | EDGAR |
| SC 13G/A | 2018-04-04 | JPMORGAN CHASE & CO | Axsome Therapeutics, Inc. | 157,881 | 0.6% | EDGAR |
| SC 13G/A | 2018-02-14 | LYTTON LAURENCE W | Axsome Therapeutics, Inc. | 982,690 | 4.2% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | Axsome Therapeutics, Inc. | 1,205,812 | 4.7% | EDGAR |
| SC 13G/A | 2018-01-16 | JPMORGAN CHASE & CO | Axsome Therapeutics, Inc. | 1,432,456 | 5.6% | EDGAR |
| SC 13G/A | 2018-01-09 | SABBY MANAGEMENT, LLC | Axsome Therapeutics, Inc. | 704,000 | 2.8% | EDGAR |
| SC 13G | 2017-12-04 | SABBY MANAGEMENT, LLC | Axsome Therapeutics, Inc. | 704,000 | 2.8% | EDGAR |
| SC 13G/A | 2017-08-10 | FMR LLC | Axsome Therapeutics, Inc. | 1,562,412 | 6.6% | EDGAR |
| SC 13G | 2017-04-27 | LYTTON LAURENCE W | Axsome Therapeutics, Inc. | 1,300,692 | 5.5% | EDGAR |
| SC 13G/A | 2017-02-14 | FMR LLC | Axsome Therapeutics, Inc. | 2,361,625 | 12.3% | EDGAR |
| SC 13G/A | 2017-01-13 | JPMORGAN CHASE & CO | Axsome Therapeutics, Inc. | - | - | EDGAR |
| SC 13G | 2016-02-02 | JPMORGAN CHASE & CO | Axsome Therapeutics, Inc. | - | - | EDGAR |
| SC 13G | 2015-12-10 | FMR LLC | Axsome Therapeutics, Inc. | 2,870,570 | 15.0% | EDGAR |
| SC 13D | 2015-12-04 | Antecip Capital LLC | Axsome Therapeutics, Inc. | 7,344,500 | 38.4% | EDGAR |